OCTANINE F 250 (50 IU/ml)

Overview

Welcome to Dwaey, specifically on OCTANINE F 250 (50 IU/ml) _ Infusion/Powder for page.
This medicine contains an important and useful components, as it consists of Coagulation factor IX.
OCTANINE F 250 (50 IU/ml) _ is available in the market in concentration 50 IU/ml and in the form of Infusion/Powder for.

OCTAPHARMA is the producer of OCTANINE F 250 (50 IU/ml) _ and it is imported from AUSTRIA, The most popular alternatives of OCTANINE F 250 (50 IU/ml) _ are listed downward .

Mode Of Action

Factor IX is used as replacement therapy in patients with haemophilia B whereby there is a genetic deficiency of factor IX.

Indication

Hemophilia B or Christmas disease

Precaution

Activity-neutralizing antibodies (inhibitors) have been detected in patients receiving factor IXcontaining products. As with all factor IX products, patients using (coagulation factor ix recombinant) should be monitored for the development of factor IX inhibitors . Patients with factor IX inhibitors may be at an increased risk of anaphylaxis upon subsequent challenge with factor IX. Patients experiencing allergic reactions should be evaluated for the presence of inhibitor. Preliminary information suggests a relationship may exist between the presence of major deletion mutations in a patient's factor IX gene and an increased risk of inhibitor formation and of acute hypersensitivity reactions. Patients known to have major deletion mutations of the factor IX gene should be observed closely for signs and symptoms of acute hypersensitivity reactions, particularly during the early phases of initial exposure to product. In view of the potential for allergic reactions with factor IX concentrates, the initial (approximately 10 - 20) administrations of factor IX should be performed under medical supervision where proper medical care for allergic reactions could be provided. Lactation: Not known if excreted in breast milk; use caution

Side Effects

>10% Headache (10.8%) 1-10% Dizziness (7.7%)
Rash (1.6-7.7%)
Injection site pain (6.2%)
Nausea (6.2%)
Urticaria (3.1-4.8%)
Rhinitis (4.6%)
Altered taste sense (4.6%)
Dyspnea (3.2%)
Fever (3.1%)
Flushing (3.1%)
Allergic reaction (1.5%) Frequency Not Defined Lethargy
Altered blood pressure (too rapid infusion)
Thrombosis (large dose)
Myocardial infarction (large dose)
DIC (large dose)
Chills
Tingling
Vomiting
Human-derived products: viral infection
Stinging at infusion site (large dose)
Hives
Anaphylaxis

Contra indication

Patients with a known history of hypersensitivity to hamster protein.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks